Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Filing Puts It Out Ahead In Venous Thromboembolism

This article was originally published in The Pink Sheet Daily

Executive Summary

Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.

Advertisement

Related Content

Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients
Hurricane Sandy Rains On User Fee Dates, Advisory Committees
Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
Xarelto Expanded Indication May Depend On Containing Worries About Bleeding
Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
Eliquis Delay Fuels Speculation About Advisory Committee Meeting
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel